Repositorio Dspace

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

Mostrar el registro sencillo del ítem

dc.contributor.author Berenguer, Ruben
dc.contributor.author Gila, Ana
dc.contributor.author Espinosa, Dolores
dc.contributor.author Salmeron, Javier
dc.contributor.author Belen-Martin, Ana
dc.contributor.author Munoz-de-Rueda, Paloma
dc.contributor.author Quiles, Rosa
dc.contributor.author Vinaixa, Carmen
dc.contributor.author Manuel-Pascasio, Juan
dc.contributor.author Sánchez-Ruano, Juan-José
dc.contributor.author Angel-Serra, Miguel
dc.contributor.author Diago, Moises
dc.contributor.author Romero-Gomez, Manuel
dc.contributor.author María-Navarro, José
dc.contributor.author Testillano, Milagros
dc.contributor.author Fernández, Conrado
dc.contributor.author Carmona, Isabel
dc.contributor.author Pons-Miñano, José-Antonio
dc.contributor.author Jorquera, Francisco
dc.contributor.author Rodríguez, Francisco-Javier
dc.contributor.author Perez, Ramon
dc.contributor.author Montero, José-Luis
dc.contributor.author Granados, Rafael
dc.contributor.author Fernández, Miguel
dc.date.accessioned 2026-10-21T06:12:20Z
dc.date.available 2026-10-21T06:12:20Z
dc.date.issued 2015
dc.identifier.citation Salmerón J. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. WJG. 2015;21(30):9163. doi:10.3748/wjg.v21.i30.9163
dc.identifier.issn 1007-9327
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28750
dc.description.abstract AIM: To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis. METHODS: Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis C genotype 1, treatment-naïve (TN) or treatment-experienced (TE), who underwent triple therapy with the first generation NS3/4A protease inhibitors, boceprevir (BOC) and telaprevir (TVR), in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow up. RESULTS: One thousand and fifty seven patients were included, 405 (38%) were treated with BOC and 652 (62%) with TVR. Of this total, 30% (n = 319) were TN and the remaining were TE: 28% (n = 298) relapsers, 12% (n = 123) partial responders (PR), 25% (n = 260) null-responders (NR) and for 5% (n = 57) with prior response unknown. The rate of sustained virologic response (SVR) by intention-to-treatment (ITT) was greater in those treated with TVR (65%) than in those treated with BOC (52%) (P < 0.0001), whereas by modified intention-to-treatment (mITT) no were found significant differences. By degree of fibrosis, 56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients, both TN and TE. In the analysis by groups, the TN patients treated with TVR by ITT showed a higher SVR (P = 0.005). However, by mITT there were no significant differences between BOC and TVR. In the multivariate analysis by mITT, the significant SVR factors were relapsers, IL28B CC and non-F4; the type of treatment (BOC or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients, treated with BOC (46%) or with TVR (45%). 28% of the patients interrupted the treatment, mainly by non-viral response (51%): this outcome was more frequent in the TE than in the TN patients (57% vs 40%, P = 0.01). With respect to severe haematological disorders, neutropaenia was more likely to affect the patients treated with BOC (33% vs 20%, P ? 0.0001), and thrombocytopaenia and anaemia, the F4 patients (P = 0.000, P = 0.025, respectively). CONCLUSION: In a real clinical practice setting with a high proportion of patients with advanced fibrosis, effectiveness of first-generation PIs was high except for NR patients, with similar SVR rates being achieved by BOC and TVR.
dc.language.iso eng
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.subject.mesh Adult
dc.subject.mesh Antiviral Agents/adverse effects/therapeutic use
dc.subject.mesh Biomarkers/blood
dc.subject.mesh Carrier Proteins/antagonists & inhibitors/metabolism
dc.subject.mesh Drug Therapy, Combination
dc.subject.mesh Female
dc.subject.mesh Hepacivirus/drug effects/enzymology/genetics
dc.subject.mesh Hepatitis C, Chronic/complications/diagnosis/drug therapy
dc.subject.mesh Humans
dc.subject.mesh Intention to Treat Analysis
dc.subject.mesh Intracellular Signaling Peptides and Proteins
dc.subject.mesh Liver Cirrhosis/diagnosis/drug therapy/virology
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Prospective Studies
dc.subject.mesh Protease Inhibitors/adverse effects/therapeutic use
dc.subject.mesh RNA, Viral/blood
dc.subject.mesh Recurrence
dc.subject.mesh Registries
dc.subject.mesh Spain
dc.subject.mesh Time Factors
dc.subject.mesh Treatment Outcome
dc.subject.mesh Viral Load
dc.subject.mesh Viral Nonstructural Proteins/antagonists & inhibitors/metabolism
dc.subject.mesh Serine Endopeptidases
dc.subject.mesh Nucleoside-Triphosphatase
dc.subject.mesh DEAD-box RNA Helicases
dc.subject.mesh Viral Proteases
dc.title Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 26290644
dc.relation.publisherversion http://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.3748/wjg.v21.i30.9163
dc.journal.title World Journal of Gastroenterology
dc.identifier.essn 2219-2840


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta